EF
Evelyn Fitzsimons
BC Cancer Agency, University College London, University of Exeter
Research areas: Medicine · Hematology · Multiple Myeloma Research and Treatments · Cancer Genomics and Diagnostics · Lymphoma Diagnosis and Treatment
0000-0001-9280-9971
Employment
-
BC Cancer Agency Postdoctoral Research Fellow2026 - Present
-
University College London Research Technician2025 - 2026
-
University College, London Research Technician/CARDAMON Scientific Officer2019 - 2021
Education
-
University College London PhD Cancer Immunology2021 - 2025
-
University of Exeter First Class Bachelor of Science with Honours, Medical Sciences with Professional Training Year2014 - 2018
Projects & Funding
-
Mapping Immune Determinants of Neoadjuvant Checkpoint Inhibitor Response in Early-Stage Lung Cancer EMBO
Publications (12)
- Latent effector T cells mediate immunotherapy responses in the bone marrow microenvironment Save
- Immunotherapy drug target identification using machine learning and patient-derived tumour explant validation Save
- Tumour-intrinsic features shape T cell differentiation through precursor to symptomatic multiple myeloma Save
- 73 Real-world external validation of a novel radiomics model for prediction of pulmonary nodule malignancy Save
- A pan-cancer single-cell RNA-seq atlas of intratumoral B cells Save
- Developing a Flow Cytometric Signature of Carfilzomib Responsiveness in Myeloma Save
- Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma. Save
- Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma. Save
- A Clinically Validated Targeted Capture Panel to Identify Translocations, Copy Number Abnormalities, and Mutations in Multiple Myeloma Save
- Autophagy Blockade Disrupts Myeloma Cell Recovery from Proteasome Inhibition and Enhances Apoptosis Save
- Increased Immune-Regulatory Receptor Expression on Effector T Cells as Early Indicators of Relapse Following Autologous Stem Cell Transplantation for Multiple Myeloma. Save
- Obtusaquinone: A Cysteine-Modifying Compound That Targets Keap1 for Degradation. Save